DAMORA THERAPEUTICS INC
DMRANASDAQ🏆 #2181 by market capEarnings Oct 30US Equity
$22.06▲ $0.46 (+2.11%)
Pre-market · at closeTrack DMRA
Get earnings, price moves & breaking news on Telegram
24h▲ 2.1%
7d▲ 4.6%
14d▲ 19.2%
30d▲ 3.7%
ytd▼ 1.4%
1y▲ 196.0%
🏦Market Cap
$1.36B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $21.49 – $23.01
- 52-Week Range
- $16.50 – $34.89
- Volume (shares)
- 34,572
- Avg Volume (shares)
- —
- Shares Outstanding
- 61.7M
- Next Earnings
- 2026-10-30
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-139.34
- Dividend Yield
- —
- Dilution (1yr)
- +28.5%
DAMORA THERAPEUTICS INC
DMRAFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$211M▲ +1148.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$7M▼ −63.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.7M▲ +28.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$258M▲ +$245M YoY
StockOtter · stockotter.spaceAbout DAMORA THERAPEUTICS INC
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
16 analysts
Strong Buy6
Buy9
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.